Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03329274 · ClinicalTrials.gov registry record
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
A clinical trial of Erdheim-Chester Disease, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT03329274: Recruiting study of Erdheim-Chester Disease, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03329274 is a study of Erdheim-Chester Disease that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 500 participants, below the 1,569-participant average among 4 other Erdheim-Chester Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03329274, a study of Erdheim-Chester Disease, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators want to understand more about what kinds of health problems are caused by histiocytosis, what happens as a result of different treatments, and how ECD affects people's lives, their feelings and their attitudes. The investigators also want to learn how these things change over time for people with these conditions. To try to figure this out, doctors would like to collect information about people who have histiocytosis and how they are treated for this disease. Some participants will be asked to complete a brief interview over the telephone. Only a limited number of interviews will take place, and not everyone will be asked to participate in the interview. It is okay if the participant does not want to participate in the interview portion. If this is the case, the participant should let the study team member know when contacted.
Primary Outcome
This ECD and Other Histiocytoses registry is motivated to capture comprehensive clinical information as well as patient-centered data about ECD and Other Histiocytoses patients.
Conditions Studied
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2017-10-26 |
| Est. Completion | 2026-10 |
What NCT03329274 shows while recruiting
NCT03329274 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,569-participant average among 4 other Erdheim-Chester Disease trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Erdheim-Chester Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03329274 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03329274 about?
NCT03329274 is a clinical study titled "Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses". The investigators want to understand more about what kinds of health problems are caused by histiocytosis, what happens as a result of different treatments, and how ECD affects people's lives, their feelings and their attitudes. The investigators also want to learn how these things change over time ...
What is the current status of trial NCT03329274?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2017-10-26. Estimated completion is 2026-10.
What conditions does trial NCT03329274 study?
This clinical trial studies the following conditions: Erdheim-Chester Disease.
Who is sponsoring clinical trial NCT03329274?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03329274 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erdheim-Chester Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
RECRUITING · Early Phase 1
-
Histiocytic Disorder Follow-up Study
RECRUITING
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI